Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | PRKCA | P17252 | 4/20 | 0.80 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.80 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.80 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.66 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.66 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL8210923 | 1.00 | LMNA (0.82) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Glycerin SCHEMBL27628570 | 1.00 | LMNA (0.82) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Glycerin SCHEMBL21525383 | 1.00 | LMNA (0.82) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Tripalmitin SCHEMBL16653055 | 1.00 | LMNA (0.82) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Glycerin SCHEMBL27721791 | 0.96 | LMNA (0.75) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Triheptanoin SCHEMBL1007894 | 0.95 | LMNA (0.82) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Tricaprilin SCHEMBL28300328 | 0.95 | LMNA (0.82) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL15111355 | 0.95 | LMNA (0.82) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| Glycerin SCHEMBL15758192 | 0.95 | PRKCA (0.88) | LMNAALDH1A1PRKCAPRKCEPRKCQ | |
| SCHEMBL19301001 | 0.94 | LMNA (0.80) | LMNAALDH1A1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539313-B2 | Microbial removal | CAPRETTO EHF. (IS) | 2026-02-03 | — | — | US | claimed |
| EP-3934753-B1 | MICROBIAL REMOVAL | CAPRETTO EHF (IS) | 2025-11-05 | — | — | EP | claimed |
| US-20230107742-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | CAPRETTO EHF (IS) | 2023-04-06 | — | — | US | claimed |
| US-11337949-B2 | Thermostable formulation of biologically active substances | CAPRETTO EHF. (IS) | 2022-05-24 | — | — | US | claimed |
| US-20220152092-A1 | MICROBIAL REMOVAL | CAPRETTO EHF. (IS) | 2022-05-19 | — | — | US | claimed |
| EP-3934753-A1 | MICROBIAL REMOVAL | Capretto EHF. (IS) | 2022-01-12 | — | — | EP | claimed |
| EP-3471702-B1 | STABLE FORMULATION OF ANTIMICROBIAL LIPIDS | CAPRETTO EHF (IS) | 2021-12-29 | — | — | EP | claimed |
| EP-3471541-B1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBIAL EFFECTS OF LIPIDS | CAPRETTO EHF (IS) | 2021-05-05 | — | — | EP | claimed |
| US-20190209510-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | CAPRETTO EHF. (IS) | 2019-07-11 | — | — | US | claimed |
| US-20190209511-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | CAPRETTO EHF. (IS) | 2019-07-11 | — | — | US | claimed |
| EP-3471541-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBIAL EFFECTS OF LIPIDS | Capretto EHF. (IS) | 2019-04-24 | — | — | EP | claimed |
| EP-3471702-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | Capretto EHF. (IS) | 2019-04-24 | — | — | EP | claimed |
| WO-2017221276-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBIAL EFFECTS OF LIPIDS | CAPRETTO EHF. (IS) | 2017-12-28 | — | — | WO | claimed |
| WO-2017221275-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | CAPRETTO EHF. (IS) | 2017-12-28 | — | — | WO | claimed |
| US-12539313-B2 | Microbial removal | CAPRETTO EHF. (IS) | 2026-02-03 | — | — | US | disclosed |
| EP-3934753-B1 | MICROBIAL REMOVAL | CAPRETTO EHF (IS) | 2025-11-05 | — | — | EP | disclosed |
| CN-118613254-A | Granules containing Progerinin and pouch using the same | PRG科技株式会社 | 2024-09-06 | — | — | CN | disclosed |
| EP-3471702-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | Capretto EHF. (IS) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221276-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBIAL EFFECTS OF LIPIDS | CAPRETTO EHF. (IS) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017221275-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | CAPRETTO EHF. (IS) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107742-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | APOL1, MGLL, FABP2 | LMNA 3018/4885ALDH1A1 299/4885PRKCA 4472/4885 |
| US-20190209510-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | APOL1, MGLL, FABP2 | LMNA 3018/4885ALDH1A1 299/4885PRKCA 4472/4885 |
| US-12539313-B2 | Microbial removal | CUTA, MIF, PCNA | LMNA 2232/4885ALDH1A1 1458/4885PRKCA 2866/4885 |
| US-11337949-B2 | Thermostable formulation of biologically active substances | MGLL, DAGLA, DDOST | LMNA 2166/4885ALDH1A1 939/4885PRKCA 2734/4885 |
| US-20190209511-A1 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | MGLL, DAGLA, DDOST | LMNA 2166/4885ALDH1A1 939/4885PRKCA 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.